 Bellerophon Therapeutics, Inc. BLPH, a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that expanded access treatment with the INOpulse inhaled nitric oxide system iNO was initiated for the first time in a patient with a diagnosis of the novel coronavirus disease COVID-19 at the University of Miami School of Medicine. The treatment follows the recent decision by the U.S. Food and Drug Administration FDA to grant emergency expanded access that allows INOpulse to immediately be used for the treatment of COVID-19 under the care and supervision of their physician. Based on previous studies that demonstrate the benefits of iNO in oxygenation and immune response, INOpulse has the potential to be used as a viable treatment option for COVID-19, said the treating physician, Roger Alvarez, DO, MPH, Assistant Professor, University of Miami School of Medicine. 